Side-by-side comparison of AI visibility scores, market position, and capabilities
Digital mental health platform delivering evidence-based CBT programs, Dublin Ireland, acquired by Amwell, serves 500+ health systems and payers globally.
SilverCloud Health is a Dublin, Ireland-based digital mental health platform founded in 2012 at Trinity College Dublin. The company specializes in delivering structured, evidence-based cognitive behavioral therapy (CBT) programs through an asynchronous digital format supported by a trained human reviewer. SilverCloud was acquired by Amwell in 2021, integrating its digital mental health programs into Amwell's broader virtual care platform serving health systems, health plans, and employers.\n\nThe platform offers more than 20 condition-specific programs covering depression, anxiety, insomnia, chronic pain, diabetes, and workplace stress, among others. Each program is built on clinically validated CBT frameworks and follows a structured curriculum over six to eight weeks. Users work through modules independently and receive feedback and encouragement from a trained human supporter, a model known as supported self-management that has shown strong outcomes in peer-reviewed research.\n\nSilverCloud serves more than 500 health systems, insurers, and employers across the United Kingdom, Ireland, and the United States. Its clinical credibility is underpinned by a robust evidence base of over 90 published research studies, making it one of the most rigorously evaluated digital mental health interventions available. Following the Amwell acquisition, SilverCloud has expanded its reach through Amwell's existing hospital and health plan relationships.
mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.